{
  "abstract": "BackgroundOcular adverse events may affect tolerability during long-term endocrine therapy for breast cancer, but comparative real-world evidence remains limited. We characterized ocular adverse-event reporting patterns using the FDA Adverse Event Reporting System (FAERS) and VigiAccess.MethodsFAERS reports from Q1–2004 to Q1–2026 involving seven endocrine therapies were analyzed. Drug-specific signals were assessed using reporting odds ratio (ROR) and information component (IC) within a breast cancer indication-restricted, primary-suspect reference population. Class comparisons used multivariable logistic regression with Benjamini–Hochberg false-discovery-rate correction. Age, ovarian function suppression (OFS), and time to onset (TTO) were evaluated; VigiAccess was descriptive.ResultsAmong 42,851 eligible reports, 2,528 contained ocular adverse events. Tamoxifen showed the broadest signal spectrum, while aromatase inhibitors (AIs) showed ocular-surface and posterior-segment signals. No ocular Preferred Terms met signal criteria for toremifene or elacestrant. FDR-adjusted comparisons showed broader retinal, macular, optic nerve, corneal, and vitreous reporting with selective estrogen receptor modulators (SERMs), particularly versus AIs. Among SERM users, age ≤45 years showed lower reporting odds than age 45–60 years (aOR 0.67, 95% CI 0.46–0.94). Concomitant OFS showed lower reporting odds among AI users (aOR 0.43, 95% CI 0.28–0.63), interpreted as exploratory. Median TTO was 79, 77, and 491 days for AIs, selective estrogen receptor degraders (SERDs), and SERMs.ConclusionsOcular adverse-event reporting differed across endocrine therapies. These findings generate hypotheses for future pharmacoepidemiological, clinical, and mechanistic investigation but should not be interpreted as incidence, causality, or differential clinical risk.",
  "abstract_shown": true,
  "affiliations": [],
  "article_type": "Original Research",
  "arxiv": null,
  "author_total": 5,
  "authors": [
    {
      "name": "Xiaoping Wang"
    },
    {
      "name": "Wenzi Zuo"
    },
    {
      "name": "Chengzhi Zhang"
    },
    {
      "name": "Ben Liu"
    },
    {
      "name": "Bin Zhu"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/5vyn99q4vvtga.bib",
  "cited_by": 0,
  "doi": "10.3389/fonc.2026.1970118",
  "fulltext_url": null,
  "id": "5vyn99q4vvtga",
  "issns": [
    "2234-943X"
  ],
  "landing_url": "https://www.frontiersin.org/articles/10.3389/fonc.2026.1970118",
  "language": null,
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "feed-journal",
      "medicine/oncology"
    ]
  ],
  "openalex": null,
  "pdf_url": null,
  "pmcid": null,
  "pmid": null,
  "published": "2026-11-02",
  "publisher": "Frontiers Media SA",
  "ris": "https://research.draconitic.com/paper/5vyn99q4vvtga.ris",
  "sources": [
    {
      "first_seen": "2026-11-02T06:20:24Z",
      "native_id": "10.3389/fonc.2026.1970118",
      "source": "feed-frontiers",
      "url": "https://www.frontiersin.org/articles/10.3389/fonc.2026.1970118"
    },
    {
      "first_seen": "2026-11-02T12:24:06Z",
      "native_id": "10.3389/fonc.2026.1970118",
      "source": "crossref",
      "url": "https://www.frontiersin.org/articles/10.3389/fonc.2026.1970118/full"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "feed-journal:medicine/oncology",
      "subfield": "oncology"
    }
  ],
  "title": "Ocular adverse event profiles associated with endocrine therapies for breast cancer: a global pharmacovigilance study using FAERS and VigiAccess",
  "title_text": "Ocular adverse event profiles associated with endocrine therapies for breast cancer: a global pharmacovigilance study using FAERS and VigiAccess",
  "type": "peer-reviewed",
  "updated_at": "2026-11-04T00:26:54Z",
  "url": "https://research.draconitic.com/paper/5vyn99q4vvtga",
  "venue": "Frontiers in Oncology",
  "versions": []
}